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Abstract
Introduction Obesity is a disorder characterized by a disproportionate increase in body weight in relation to height, mainly 
due to the accumulation of fat, and is considered a pandemic of the present century by many international health institutions. 
It is associated with several non-communicable chronic diseases, namely, metabolic syndrome, type 2 diabetes mellitus 
(T2DM), cardiovascular diseases (CVD), and cancer. Metabolomics is a useful tool to evaluate changes in metabolites due 
to being overweight and obesity at the body fluid and cellular levels and to ascertain metabolic changes in metabolically 
unhealthy overweight and obese individuals (MUHO) compared to metabolically healthy individuals (MHO).
Objectives We aimed to conduct a systematic review (SR) of human studies focused on identifying metabolomic signatures 
in obese individuals and obesity-related metabolic alterations, such as inflammation or oxidative stress.
Methods We reviewed the literature to identify studies investigating the metabolomics profile of human obesity and that 
were published up to May 7th, 2019 in SCOPUS and PubMed through an SR. The quality of reporting was evaluated using 
an adapted of QUADOMICS.
Results Thirty-three articles were included and classified according to four types of approaches. (i) studying the metabolic 
signature of obesity, (ii) studying the differential responses of obese and non-obese subjects to dietary challenges (iii) studies 
that used metabolomics to predict weight loss and aimed to assess the effects of weight loss interventions on the metabolomics 
profiles of overweight or obese human subjects (iv) articles that studied the effects of specific dietary patterns or dietary 
compounds on obesity-related metabolic alterations in humans.
Conclusion The present SR provides state-of-the-art information about the use of metabolomics as an approach to under-
standing the dynamics of metabolic processes involved in human obesity and emphasizes metabolic signatures related to 
obesity phenotypes.
Keywords Metabolomics · Obesity and overweight · Metabolic profiling · Weight loss · Dietary intervention
1  Background
Obesity is a disorder characterized by a disproportion-
ate increase in body weight in relation to height, mainly 
due to the accumulation of fat. Obesity is considered a 
pandemic of the present century by the World Health 
Organization (WHO) and other international organiza-
tions (Abarca-Gómez et al. 2017; World Health Organi-
zation 2014). Obesity is associated with the development 
of important non-communicable chronic diseases, namely, 
hypertension, metabolic syndrome, type 2 diabetes mel-
litus (T2DM), cardiovascular diseases (CVD), obstructive 
sleeping apnea, osteoarthropathies and cancer (GBD 2015 
Obesity Collaborators et al. 2017; Williams et al. 2015).
Worldwide, obesity has nearly tripled since 1975, and in 
2016, more than 1.9 billion adults aged 18 years and older 
(39% of the global population) were overweight. Of these 
individuals, over 650 million (13% of the total population) 
were obese. Moreover, 41 million children under the age 
of five were overweight, and over 340 million children and 
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adolescents aged 5–19 were overweight or obese (World 
Health Organization 2018).
Obesity is usually diagnosed by estimating the body 
mass index (BMI), which is calculated as the ratio of body 
weight (kg) and height squared  (m2), allowing physicians 
to classify individuals by grade from overweight to morbid 
obesity (World Health Organization 2018). However, this 
simple and useful index does not evaluate the metabolic 
alterations frequently associated with obesity, which in 
turn are closely related to the existence of insulin resist-
ance (IR) in peripheral tissues (Cañete et al. 2007) or 
immunological disorders occurring as a consequence of 
the establishment of a low-level inflammatory process 
derived from the activation of the innate immune system 
(Hotamisligil 2006). The latter process also leads to IR 
and altered glucose and lipid metabolism (Bastard et al. 
2006), as well as the secretion of numerous pro-inflam-
matory cytokines (Tilg and Moschen 2006) and factors 
involved in angiogenesis and blood coagulation (Brestoff 
and Artis 2015; Caputo et al. 2017). Additionally, adi-
pocyte hypertrophy induces the accumulation of reactive 
oxygen species due to endoplasmic reticulum dysfunction 
(Hotamisligil 2010) and the activation of cell inflamma-
tory signaling cascades (Lee and Lee 2014). Many adi-
pokines and inflammatory factors have been suggested as 
biomarkers of obesity (Gil-Campos et al. 2004). In fact, 
in obese subjects, the expression of many genes related to 
cell metabolism and production of adipokines is signifi-
cantly altered (Aguilera et al. 2015; Gil et al. 2007; Kim 
and Park 2010).
Substantial controversy exists regarding whether obe-
sity should be considered a disease (Vallgårda et al. 2017). 
Within the obese population, clinicians can distinguish 
between metabolically healthy obese (MHO) and metabol-
ically unhealthy obese (MUHO) subjects. Increased blood 
pressure, hyperlipidemia, hyperglycemia, hyperuricemia 
and increased peripheral IR are frequently reported in 
MUHO subjects (Badoud et al. 2015a, b; Rupérez et al. 
2018).
Metabolomics is defined as a technological tool that aims 
to detect and measure changes in the profiles and levels of 
low molecular weight metabolites (< 1500 Da) in cells, tis-
sues, organs, systems or whole organisms in response to a 
genetic variation or physiological or pathological condition 
(Gibney et al. 2005). Therefore, metabolomics enlightens 
as a useful tool to evaluate changes in metabolites due to 
overweight and obesity at the cellular level, i.e., visceral 
and omental white adipose tissues (AT), brown AT, skel-
etal muscle, liver, among others, and body fluid level, i.e., 
plasma, urine, and human milk. Also, this analytical tool 
is of keen interest in ascertaining the metabolic fingerprint 
(a recognizable chemical pattern specific of an individual 
sample) related to metabolically unhealthy obese individuals 
compared to metabolically healthy individuals (Badoud et al. 
2015b).
Metabolomics comprises qualitative and quantitative 
analyses of intracellular and intercellular metabolites, usu-
ally using two main distinct analytical approaches: (a) non-
targeted metabolite profiling, intended as a comprehensive 
analysis without further knowledge of the features covered 
and which might result in the identification and characteri-
zation of a large variety of metabolites that can cluster into 
recognizable patterns; and (b) targeted metabolite profiling, 
that is focused on a reliable quantitative measurement of 
the variations in metabolites involved in a number of meta-
bolic pathways (e.g., amino acids (AA) and their deriva-
tives) based on an understanding of their biological roles 
in those pathways (Park et al. 2015). These methods differ 
in numerous aspects, such as the complexity of the sam-
ple preparation procedures, the experimental precision, the 
range of features (metabolites) detected, and the quantifica-
tion level (relative versus absolute) (Rangel-Huerta and Gil 
2016). Those characteristics prompt researchers to establish 
specific objectives for each approach, such as generating a 
hypothesis or testing a previously developed hypothesis 
(Putri et al. 2013).
Over the last decade, numerous reports and reviews 
have addressed the metabolic changes associated with 
obesity in both humans and animal models (Abu Bakar 
et al. 2015; Adams 2011; Calvani et al. 2014; Du et al. 
2013; Fiehn et  al. 2010; Gogna et  al. 2015; He et  al. 
2012; Hivert et al. 2015; Kim and Park 2010; Kim et al. 
2010a; Mihalik et al. 2012; Moore et al. 2013; Morris 
et al. 2012; Newgard 2017; Newgard et al. 2009; Ober-
bach et al. 2011; Pietiläinen et al. 2007; Rauschert et al. 
2014, 2016; Rauschert et al. 2017; Rauschert et al. 2017; 
Shore and Cho 2016; Tulipani et al. 2016a; Villarreal-
Pérez et al. 2014; Wahl et al. 2012; Williams et al. 2006; 
Xie et al. 2012; Zeng et al. 2010; Zhang et al. 2013; Zhao 
et al. 2016a, b). Many of them describe changes in the 
metabolic profile associated with obesity and diabetes, and 
notably features associated with IR (Abu Bakar et al. 2015; 
Adams 2011; Fiehn et al. 2010; Gogna et al. 2015; Mihalik 
et al. 2012; Newgard 2017; Newgard et al. 2009; Rauschert 
et al. 2016; Villarreal-Pérez et al. 2014; Zhao et al. 2016a, 
b), and the majority report the results of targeted analy-
ses. Indeed, the identified metabolites can serve as bio-
markers of the pathophysiological mechanisms involved 
in the development of obesity and, subsequently, T2DM. 
Elevated levels of branched-chain AAs (BCAAs) (leucine, 
isoleucine, and valine) and aromatic AAs (phenylalanine, 
tyrosine, tryptophan and methionine), as well as some of 
their tissue metabolites, have been detected in both sub-
jects with obesity and diabetes, whereas glutamine and 
glycine levels are decreased (Adams 2011; Mihalik et al. 
2012; Morris et al. 2012; Newgard 2017; Newgard et al. 
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2009; Rauschert et al. 2017), although the results have 
not always been consistent (Fiehn et al. 2010; Kim et al. 
2010b; Oberbach et al. 2011; Wahl et al. 2012). The levels 
of other non-protein nitrogen compounds, such as nucleo-
tides, nucleosides, and their metabolites, namely, uridine 
and uric acid, vary considerably, depending on the degree 
of IR in obese subjects (Fiehn et al. 2010; Park et al. 2015; 
Wahl et al. 2012). Regarding lipid metabolites, the lev-
els of some fatty acids (FAs), e.g., palmitic, palmitoleic, 
stearic, and oleic acids, and stearoyl carnitine are elevated 
in obese subjects (Park et al. 2015). Likewise, the levels of 
some lysophospholipids of both choline and ethanolamine 
seem to be altered, although the direction of changes is not 
consistent and depend on each study (Fiehn et al. 2010; 
Gogna et al. 2015; Kim et al. 2010b; Moore et al. 2013; 
Pietiläinen et al. 2007; Wahl et al. 2012). Concerning car-
bohydrates, the concentrations of glucose, fructose, man-
nose, xylose, gluconic acid, glucuronic acid, glycerol and 
lactate in plasma are usually increased, whereas the con-
centrations of glycerol-3-phosphate and other metabolites 
are decreased in obese men (Fiehn et al. 2010; Gogna et al. 
2015; Moore et al. 2013; Park et al. 2015). A summary of 
the changes in the major metabolites in subjects with obe-
sity and diabetes obtained using a targeted metabolomics 
approach has been previously reported (Putri et al. 2013).
In this context, we aimed to perform a systematic review 
(SR) of human studies focused on identifying metabolomic 
signatures in obese individuals and obesity-related metabolic 
alterations, such as inflammation or oxidative stress; we con-
sidered the targeted and nontargeted approaches as different 
and separate strategies within the metabolomics analyses. 
Furthermore, we included studies evaluating the metabolic 
signature and its modulation by dietary interventions, such 
as dietary challenges or weight loss programs, in humans.
2  Methods
The present SR was designed to review the state-of-the-art 
research related to the use of metabolomics as an approach 
to understanding the dynamics of metabolic processes 
involved in human obesity.
This review was conducted following the PRISMA-P 
(Preferred Reporting Items for SR and Meta-Analysis Pro-
tocols) statement (Moher et al. 2015) (see Fig. 1).
2.1  Inclusion and exclusion criteria
Studies employing cross-sectional, prospective, parallel, and 
crossover designs were considered. The sample size was not 
restricted. Articles, or at least the abstract, must have been 
written in English or Spanish. Conference abstracts, reviews, 
meta-analyses, case reports, ecological studies, and letters 
to the editor were excluded.
2.2  Search strategy and eligibility criteria
Studies should have focused on the metabolic profile of 
obese humans or their regulation by weight loss interven-
tions, dietary products, or dietary challenges to be con-
sidered for inclusion in the SR. Studies of overweight or 
obese subjects in which the outcomes were strictly related 
to the study of obesity were included. All the studies utiliz-
ing a metabolomics approach, including but not limited to 
nuclear magnetic resonance (NMR) or MS (coupled to dif-
ferent types of chromatography) of urine or plasma samples, 
were included. Studies published up to May 7th, 2019, were 
included.
2.3  Literature search
We performed an SR of studies published in English or Span-
ish of the populations included in the following electronic 
databases without an age limit: MEDLINE (via PubMed) 
and SCOPUS. Figure 1 shows the main steps of the literature 
search. Studies were identified in the databases by applying 
a publication date of May 7th, 2019, human subjects, and 
the following search MeSH terms (exclusive of PubMed): 
(“Metabolome”[Majr] OR “Metabolomics”[Majr]) AND 
“Obesity”[Majr] AND “humans”[MeSH Terms].
MeSH terms are restricted to medical databases such 
as PubMed. Therefore, as SCOPUS has more extensive 
coverage than PUBMED, the search was done using 
metabolome, metabolomics, and other additional terms. 
The search in SCOPUS was filtered by articles using the 
following equation: (“obesity” OR “overweight”) AND 
(“metabolic profiling” OR “metabolic fingerprint” or 
metabolomics).
2.4  Study selection and data extraction
First, both the titles and abstracts of publications yielded 
by the search were reviewed independently by two review-
ers, ODHR and BPV and studies that did not meet the 
established language, subject matter, participant, design 
and outcome criteria were excluded (see Fig. 1).
ODHR and BPV input the data into the database; one 
additional reviewer (AG) resolved any discrepancies. After 
selecting the final list of articles to be included, the authors 
elaborated a classification according to the objectives and 
approach of the studies to facilitate the interpretation of 
the results.
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2.5  Quality assessment
The quality of the selected articles included in the present SR 
was evaluated using the QUADOMICS tool, which has been 
employed in other metabolomics reviews (Lumbreras et al. 
2008; Zhang et al. 2017; Zhao et al. 2016a, b). This tool was 
developed to evaluate quality issues specific to omics research 
and has been used to assess the quality of diagnostic studies in 
a highly dynamic field that faces the challenge of sieving many 
recently published results (Lumbreras et al. 2008). Because of 
the wide range of types of studies, we selected specific items 
that covered the major domains. The items and the evaluation 
criteria are included as Supplementary Material (Supplemental 
Table 1).
3  Result
3.1  Selection of metabolomics studies investigating 
obesity
The process for the selection of studies after the literature 
search is described in Fig. 1. Finally, we reviewed 60 stud-
ies that met established inclusion criteria and were evaluated 
by quality according to the QUADOMICS evaluation (see 
Supplemental Table 1). According to the type of approach 
reported on the studies, we have divided the results into four 
blocks. The first block includes studies designed to deter-
mine the metabolic signature of obesity; 15 of which used an 
untargeted approach (Fattuoni et al. 2018; Ruebel et al. 2019; 
Houttu et al. 2018; Sorrow et al. 2019; Butte et al. 2015; Kim 
et al. 2010b; Xie et al. 2014; Hanzu et al. 2014; Zhao et al. 
2016a, b; Foerster et al. 2015; Bagheri, et al. 2019, Cirulli 
et al. 2019, Yu et al. 2018, Marco-Ramell et al. 2018, Piening 
et al. 2018), 14 used targeted metabolite profiling (Wahl et al. 
2012; Gawlik et al. 2016; Newgard et al. 2009; Baker et al. 
Fig. 1  PRISMA 2009 flow 
diagram
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2015; Kraus et al. 2016; Feldman et al. 2019; Maltais-Payette 
et al. 2018; Carayol et al. 2017; Bagheri et al. 2018; Wang 
et al. 2018; Ho et al. 2016; Haufe et al. 2016; Stroeve et al. 
2016; Tulipani et al. 2016a, b), and one designed the metabo-
lomics study using a combination of both approaches (Cho 
et al. 2017) (Table 1). The second block includes five studies 
focused on studying the differential responses of obese and 
non-obese subjects to dietary challenges (Table 2) (Badoud 
et al. 2015b; Baker et al. 2015; Geidenstam et al. 2014; Bak 
et al. 2018). The third block comprises three studies that 
used metabolomics to predict weight loss (Geidenstam et al. 
2017a, b; Stroeve et al. 2016) and 11 randomized clinical trials 
(RCTs) aimed to assess the effects of weight loss interventions 
(both hypocaloric diet programs and exercise interventions) 
on the metabolomic profiles of overweight or obese human 
subjects (Table 2) (Almanza-Aguilera et al. 2018; Duft et al. 
2017; Kang et al. 2018; Leal-Witt et al. 2018; Meucci et al. 
2017; Mills et al. 2019; Munukka et al. 2018; Palau-Rodriguez 
et al. 2019; Perez-Cornago et al. 2014; Zheng et al. 2016a, b). 
Additionally, the fourth block includes 11 articles that studied 
the effects of specific dietary patterns or dietary compounds 
on obesity-related metabolic alterations in humans, such as 
inflammation or oxidative stress (Table 3) (Baldrick et al. 
2018; Gu et al. 2013; Hernández-Alonso et al. 2019; Hibberd 
et al. 2019; Kim et al. 2013; Kim et al. 2017; Mayengbam 
et al. 2019; Nieman et al. 2012a, b; Romo-Hualde et al. 2018; 
Xu et al. 2018). 
3.2  Metabolomic profiling of obesity
3.2.1  Untargeted analysis
Three studies focused on profiling the obesity during preg-
nancy (Table 1). The analysis of placenta samples from 
obese women reveals a potentially altered metabolism as 
reflected by the dysregulation of several pathways. Metabo-
lites associated with the antioxidant defense system, nucle-
otide production, as well as lipid metabolism and energy 
production were modified. A specific serum fatty acid profile 
characterized by low levels of LC-PUFA derivatives, arachi-
donic acid, and DHA, and high levels of palmitic acid were 
observed (Fattuoni et al. 2018).
Furthermore, the study of the follicular fluid from over-
weight and obese women presented similar oxidative stress 
and lipid metabolism alterations. Elevated concentrations of 
uric acid and several unknown lipids, as well as a decrease 
of 2-ketoglucose dimethyl acetal, aminomalonate, two 
unknown primary metabolites, and two unknown complex 
lipids in the overweight and obese woman (Ruebel et al. 
2019). Moreover, using NMR, serum metabolic profiling 
revealed a different lipid profile in pregnant women when 
compared with overweight. Specifically, the obese preg-
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lipoprotein (VLDL) and lower high-density lipoprotein par-
ticles (HDL); lower proportions of ω-6 fatty acid, 18:2 lin-
oleic acid and PUFAs of total FAs, as well as the estimated 
degree of unsaturation of FAs (Houttu et al. 2018).
Two studies performed untargeted metabolomics analysis 
in children (Sorrow et al. 2019; Butte et al. 2015), (Table 1). 
First, the study of the umbilical cord from children develop-
ing obesity by age 3–5 years old provided valuable informa-
tion (Sorrow et al. 2019). Those children with elevated con-
centrations of medium and very long-chain FAs (LCFAs), 
such as stearate, oleate or palmitate at birth, developed obe-
sity later in life. Moreover, the authors reported an associa-
tion between obesity and several acetaminophen metabolites 
at birth, including 3-(N-acetyl-l-cysteine-S-yl) acetami-
nophen, 2-hydroxyacetaminophen sulfate, 2-methoxyaceta-
minophen glucuronide, and p-acetamidophenyl glucuronide.
Butte et al. (2015) reported that the relative plasma con-
centrations of BCAAs (leucine, isoleucine, and valine), 
their catabolites (2-methylbutyrylcarnitine, 3-methyl-2-ox-
obutyrate, and isovalerylcarnitine), propionylcarnitine (C3) 
and butyrylcarnitine (C4) were significantly increased in 
obese children compared with non-obese children (Butte 
et al. 2015). The authors (Butte et al. 2015) also observed 
increased levels of both polar and non-polar AAs (gluta-
mate, lysine, tyrosine and phenylalanine, and alanine, 
respectively), polyamines, several gamma-glutamyl dipep-
tides and polypeptides in obese children. In contrast, aspar-
agine, aspartate, glycine, serine, and histidine levels were 
decreased. Notably, significantly higher levels of the ketone 
bodies containing α-hydroxybutyrate and α-ketobutyrate 
were observed in the obese children, but lower concentra-
tions of lysophospholipids (glycerophosphocholines and 
glycerophosphoethanolamines) and decarboxylated FAs 
(dodecanedioate, tetradecanedioate, and 2-hydroxyde-
canoate) were observed compared with non-obese children. 
Significantly lower β-hydroxybutyrate levels were also 
observed in obese children than in non-obese children. Fur-
thermore, markedly higher levels of steroids, such as dehy-
droepiandrosterone sulfate (DHEA-S), were detected in 
obese children. Additionally, higher mannose and pyruvate 
levels and lower glycerate and citrate levels were measured 
in obese children than in non-obese children. Higher levels 
of purine and pyrimidine metabolites were observed in obese 
children. Remarkably, tyrosine was considered the highest-
ranked metabolite based on its contribution to the obesity 
classification (Butte et al. 2015).
Regarding adults, 11 untargeted studies were included 
in the present SR (Table 1). In 2010, Kim et al. (2010b) 
reported higher levels of stearic acid and lower levels of 
oleic acid among the serum phospholipids of overweight/
obese men. Furthermore, they also identified higher con-
centrations of lysophosphatidylcholine (lysoPC) a C14:0 and 
















































































































































































































































































































































































































































































































































































Are we close to defining a metabolomic signature of human obesity? A systematic review of…
1 3






































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 O. D. Rangel-Huerta et al.
1 3
93 Page 12 of 31
lean subjects, and confirmed eight known metabolites for 
overweight/obesity men (two BCAAs (valine and leucine); 
two essential AAs (phenylalanine and tryptophan)), as well 
as critical compounds of FA synthesis and oxidation (car-
nitine, propionyl-, butyryl-, and hexanoyl-carnitine) (Kim 
et al. 2010b). Using similar platforms, Xie et al. (2014) also 
reported higher serum BCAA levels in obese men than in 
lean men; moreover, BCAA levels correlated with IR and 
were higher in obese men, but not in obese women. Interest-
ingly, they also reported high levels of propionyl-L-carnitine 
(C3) in obese men (Xie et al. 2014). More recently, Yu et al. 
(2018) found that obese men presented higher concentra-
tions in serum of phenylalanine, Phe–Phe, and tryptophan, 
and lower levels of p-cresol and p-cresol sulfate. Interest-
ingly, the levels of phenylacetamide, l-glutamine, phenyla-
cetylglutamine, indoxyl sulfate, p-cresol, and p-cresol sulfate 
were higher in the urine of obese men.
The profiles between obese males and obese females dif-
fered, namely, higher concentrations of creatine, palmitic 
acid, myristic acid, n-dodecanoic acid, cis-11,14-eicosadien-
oic acid and linoleic acid and lower concentrations of several 
lysoPCs (e.g., lysoPC a C18:2, lysoPC a C20:4, and lysoPC 
a C20:5), uric acid and 12α-hydroxy-3-oxochola-dienic acid 
in females than in males (Xie et al. 2014).
Regarding the study of AT metabolites (Table 1), Hanzu 
et al. (2014) observed higher levels of glutamine and alanine 
in the visceral AT of obese subjects, as well as decreased 
uptake of essential AAs (methionine, threonine, and lysine), 
BCAAs and serine. Also, depletion of α-ketoisocaproic 
(α-KIC) acid was observed in the subcutaneous AT (Hanzu 
et al. 2014).
Zhao et al. (2016a, b) reported the associations between 
several measures of obesity and diverse groups of plasma 
metabolites. A positive correlation between the levels of ole-
oylethanolamide (fatty amide) and the tryptophan derivative 
kynurenine, and negative correlations between mannosyl-
diinositol-phosphorylceramide (sphingolipid) levels with 
both BMI and waist circumference (WC). Moreover, auxin 
A (prenol lipid) and 12-ketoporrigenin levels were also pos-
itively correlated with BMI, whereas glutamate, Gly-Val-
Arg-Gly peptide, pristanic acid (prenol lipid), and spirolide 
E (prenol lipid) levels were associated with WC (Zhao et al. 
2016a, b).
Foerster et al. (2015) studied the relationship between 
obesity and the serum metabolome identifying two groups 
of compounds (compared with principal components) 
related to obesity. One included BCAAs and the other AA 
derivatives. These components were directly associated 
with weight, WC, BMI, body fat mass, and waist-to-height 
ratio. While another study (Piening et al. 2018) associated a 
metabolic signature comprised of 133 metabolites, mainly 
acylcarnitines (AC), FA, and lysophospholipids with BMI. 
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2019), provided a 49-metabolites signature (with similar 
compounds to those reported by Piening et al. (2018)) asso-
ciated with BMI.
A recent report from Bagheri et al. (2019) identified a 
metabolic pattern (including 19 metabolites) associated with 
obesity. From such a pattern, compounds like alanine, glu-
tamic acid, proline, tyrosine, diacyl-phosphatidylcholines, 
and LPCa C16:1 and BCAAs were higher in the obese par-
ticipants, while asparagine, serine, acyl-alkyl-phosphati-
dylcholines, and other lysoPC were higher in non-obese 
subjects.
Marco-Ramell et al. (2018) studied the signature of obe-
sity that overlaps with IR, and their design let them iden-
tify those compounds specific to the former. The authors 
reported that the presence of arachidonic, hydroxyeicosa-
tetraenoic (HETE), palmitoleic, triHETE and glycocholic 
acids, HETE lactone, leukotriene B4 and two glutamyl-pep-
tides conform a unique signature of obesity rather than of IR.
3.2.2  Targeted analysis
In children, one study (Table 1) described significantly 
decreased serum concentrations of the acyl-alkyl phos-
phatidylcholines (PC aa C34:1, PC aa C34:2, PC aa C34:3, 
PC aa C36:2, PC aa C36:3 and PC ae C38:2) and lysoPCs 
(lysoPC a C18:1, lysoPC a C18:2, and lysoPC a C20:4) in an 
obese group compared with lean subjects (Wahl et al. 2012). 
Moreover, significantly lower levels of the AAs glutamine, 
methionine, and proline were detected. In contrast, signifi-
cantly higher concentrations of two AC (C12:1 and C16:1) 
were observed in obese children than in normal-weight chil-
dren (Wahl et al. 2012).
Gawlik et al. (2016) aimed to identify steroid signatures 
in 24-h urine samples from obese children (Table 1). How-
ever, the authors did not identify any steroid profiles related 
to obesity status (Gawlik et al. 2016).
Regarding the adult population (Table  1), Newgard 
et al. (2009) observed higher levels of ethyl malonate and 
lower levels of isobutyryl glycine, isovaleryl glycine, and 
α-ketoglutarate in urine samples from obese subjects than in 
lean subjects (Newgard et al. 2009). Moreover, when focus-
ing on BCAAs (Table 1), the authors reported a signature in 
obese subjects marked by dramatically increased concentra-
tions of phenylalanine, alanine, valine, leucine/isoleucine, 
tyrosine, glutamate/glutamine, aspartate/asparagine, and 
arginine, whereas glycine levels appeared to be decreased. 
Similarly, Kraus et al. (2016) observed an inverse correla-
tion between plasma glycine levels and BMI. While plasma 
phenylalanine levels have been found to be positively cor-
related with BMI (Ho et al. 2016) (Table 1), lower levels of 
other AAs, such as glycine, histidine, methionine and cit-
rulline, have been reported in the skeletal muscle of obese 
subjects (Baker et al. 2015) (Table 1). Moreover, higher 
plasma concentrations of short-chain AC species (SCAC, 
C3, C4/4i, C5, and C5:1) were detected in obese subjects 
(Baker et al. 2015).
Additionally, Ho et al. (2016) reported positive correla-
tions between BMI and multiple metabolites in the citric 
acid cycle (isocitrate, α-ketoglutarate, and aconitate), the 
tryptophan pathway (kynurenine and kynurenic acid), the 
urea cycle (citrulline and ornithine), nucleic acid metabo-
lism (xanthosine and uric acid), and creatine-related metabo-
lites (carnitine, choline and glycerophosphocholine). Haufe 
et al. (2016) also identified a positive correlation between 
tyrosine levels and the intrahepatic fat content and correla-
tions between tryptophan and valine levels with hepatic IR.
In plasma samples from women, significantly lower 
BCAA concentrations were measured with NMR in sub-
jects with moderate-high (27 ≤ BMI < 40 kg/m2) obesity 
than in morbidly obese (MO) subjects. Alanine, proline, 
and tyrosine concentrations were lower in women with 
moderate-high obesity than in MO women. Significant dif-
ferences in the plasma levels of phosphatidylcholine species, 
such as lysoPC a C18:2, PC ae (34:3), PC ae (38:7), PC ae 
(40:6), PC ae (38:3), PC ae (40:4), and PC ae (40:8), were 
quantified between male and female subjects with MO and 
moderate-high obesity (Stroeve et al. 2016).
Cho et  al. (2017) aimed to distinguish the urinary 
metabolomic characteristics between young obese and nor-
mal-weight subjects (Table 1). Docosaenoic acid, 12-oxo-
20-carboxy-leukotriene B4, and 4α-hydroxymethyl-5α-
cholesta-8-en-3β-ol levels were strongly correlated with the 
BMI and cholesterol levels. However, in their targeted study 
using the commercial solution Absolute IDQ p180, higher 
levels of several AC (e.g., C3, C3-DC-M/C5-OH, C3-OH, 
C6:1, and C8); AAs (aspartate and histidine); biogenic 
amines, such as asymmetric dimethylarginine (ADMA), 
3,4-dihydroxyphenylalanine, putrescine and total dimethyl-
arginine; glycerophospholipids such as lysoPC a C18:0, PC 
aa C38:0, PC aa C38:6, PC aa C40:6, and PC ae C44:4; and 
the sphingolipid (SM) (OH) C14:1 were detected in obese 
adolescents. In contrast, lower levels of several AC (C4, C9, 
and C14:1-OH), arginine, asparagine, glutamine, glycine, 
isoleucine, methionine, ornithine, serine and threonine, car-
nosine, dopamine, serotonin, PC aa C28:1, PC aa C30:2, 
PC aa C34:1, PC aa C34:2, PC aa C34:4, PC aa C36:1, PC 
ae C38:5, PC ae C38:6, PC ae C44:5, SM (OH) C22:1, SM 
C16:0 and SM C24:1 were observed in obese adolescents 
than in the non-obese controls.
Other authors have opted to perform targeted analysis 
using the same commercial kit with the advantage of pro-
viding comparable results (Table 1). For instance, Tulipani 
et al. (2016a, b) concluded that serum concentrations of 
lysoPCs (lysoPC a C17:0, lysoPC a C18:1, and lysoPC a 
C18:2) show a robust inverse correlation with BMI, body 
weight and waist and hip circumference in MO adults. 
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Additionally, both choline- and ethanolamine-containing 
lysolipids acylated with margaric acid (C17:0) oleic acid 
(C18:1) and linoleic acid (C18:2) were the best classifiers 
of MO, together with diacyl and acyl-alkyl phosphocholines 
with LCFA (Tulipani et al. 2016a, b). Bagheri et al. (2018) 
reported that MHO phenotype was associated with alanine, 
tyrosine, glutamic acid, ACC18:2, acyl-lysoPC C18:1and 
c18:2, and alkyl-lysoPC C:18, and diacyl-phosphatidylcho-
lines C312:1 and C38:3. Whereas the MUHO phenotype 
was associated to tyrosine, glutamic acid, serine, proline, 
and asparagine), AC C3:0, acyl-lysoPC C18:1, C18:2, and 
C16.1, diacyl-phosphatidylcholines C32:1 C32:2, C34:2, 
and C38:3, and acyl-alkyl-phosphatidylcholine C34:3. Both 
associations were detected when compared with healthy 
individuals; however, when both phenotypes were compared 
directly, there were no differences.
3.3  Differences in response to dietary challenges 
between obese and non‑obese individuals
Badoud et al. (2015b) studied the differences in the effect of 
a high-calorie meal administered in an acute intervention of 
120 min among lean, healthy, MHO, and MUHO subjects 
(Table 2). Interestingly, the authors reported correlations 
between the levels of various BCAAs and FAs (e.g., satu-
rated myristic and palmitic acids) with glucose levels and 
the insulin AUC. Moreover, several metabolites (asparagine, 
cystine, glutamine, serine, and the carnitine-to-acetylcarni-
tine ratio) exhibited different responses among the three 
groups. In addition, the serum concentrations of the PUFAs 
linoleic acid, γ-linolenic acid, and arachidonic acid showed 
subtle changes after the meal among the obese groups.
Geidenstam et al. (2014) initially studied the response 
of subjects with impaired glucose tolerance. Briefly, the 
authors reported three significant shifts to oral glucose tol-
erance test (OGTT), including compounds with a delayed 
glucose-provoked decrease (mostly FFAs), metabolites that 
showed a rapid onset (AAs and BCAAs) and compounds 
characterized by a blunted onset (Geidenstam et al. 2014). 
Second, in subjects who experienced weight loss and a 
weight maintenance period, changes in some but not all 
components of the OGTT-elicited serum profile that dif-
fered between obese glucose-intolerant subjects and lean 
glucose-tolerant subjects were observed (Geidenstam et al. 
2014, 2016).
In a different type of challenge conducted by Baker et al. 
(2015), the authors studied the impact of a high-fat diet 
(HFD) administered for 5 days after profiling the obesity 
signature at baseline and revealed that muscle medium-chain 
AC (MCAC) (C6, C8, C10:2, C10:1, C10, and C12:1) levels 
are increased in obese subjects but decreased in lean subjects 
(Table 2). The plasma C10:1 content is also decreased in 
the lean subjects but increased in the obese subjects from 
pre- to post-HFD (Baker et al. 2015). Additionally, after the 
HFD intervention, lower glycine, histidine, methionine, and 
citrulline levels were observed in obese subjects. Moreover, 
skeletal muscle α-ketoglutarate levels were increased in the 
lean subjects from pre- to post-HFD conditions but were 
decreased in obese individuals (Baker et al. 2015). Further-
more, lean individuals exhibited decreases in MCAC (C4/4i, 
C6, C8, C10:2, C10:1 (also in plasma), C10, and C12:1) lev-
els in response to the HFD, and the obese subjects showed 
increased levels from pre- to post-HFD. Both plasma C3 
and C4/4i AC levels were elevated in the obese subjects 
compared with lean subjects.
Recently, a study focused on skeletal muscle was carried 
out in lean and obese men to explore and compare substrate 
metabolism in such tissue after fasting conditions (Table 2) 
(Bak et al. 2018). Interestingly, β-hydroxybutyrate was found 
elevated in plasma, being more pronounced in lean than 
obese. Also, plasma glycerol was increased in obese during 
12 h of fasting, and ~ 50% more in lean than obese during 
72 h of fasting.
3.4  Metabolomics of weight loss
Three interventions included in this review focused on inves-
tigating potential predictor profiles/signatures of weight loss 
interventions.
According to Stroeve et al. (2016), 57% of the variation 
in weight loss success is predicted by baseline metabolic 
parameters. For males, the models were based on plasma 
lipid species (particularly sphingomyelins and phosphatidyl-
cholines), whereas several AAs were included in the mod-
els for females, particularly in the models distinguishing 
subjects with obesity from subjects with MO (e.g., alanine, 
proline, and tyrosine were lower in women with obesity 
versus MO). The best predictive models were obtained for 
subjects with MO (including ketone bodies, triacylglycerols, 
phosphatidylcholines, AAs as valine, tyrosine, alanine, and 
proline, creatine and creatinine).
Geidenstam et  al. (2017a) identified changes in the 
plasma levels of several AAs after weight loss for nine 
months and weight maintenance in obese subjects and evalu-
ated in a replication cohort (Table 2). Of the 21 detected 
AAs, only tyrosine approached the lean reference profile (no 
initial increase) after weight loss, and this profile was main-
tained after weight maintenance (Geidenstam et al. 2017a).
Subjects enrolled in a 1-year weight loss program were 
classified into two groups according to the achievement 
(< or > 10% weight loss) (Geidenstam et al. 2017a). The 
analysis revealed that decreased levels of 1-methyladeno-
sine, alanine, proline, trans-cinnamic acid, tyrosine, and the 
BCAAs were associated with a ≥ 10% weight loss. A lower 
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baseline concentration of xylitol was predictive of a decrease 
in BMI and ≥ 10% weight loss.
Eight articles (Leal-Witt et al. 2018; Kang et al. 2018; 
Palau-Rodriguez et al. 2019; Mills et al. 2019; Almanza-
Aguilera et al. 2018; Perez-Cornago et al. 2014; Zheng et al. 
2016a, b) focused on determining the effect of weight loss on 
the metabolomics profiles of overweight and obese individu-
als. The article from Zheng et al. (2016b) was approached as 
two studies because the study design including two different 
cohorts, see below).
In prepubertal children with obesity, Leal-Witt et al. 
(2018) reported a decrease of urine trimethylamine N-oxide 
(TMAO) after following a Mediterranean diet with increased 
physical activity for 6 months (Table 2). Of the 32 distinct 
metabolites identified, highlighted metabolites altered after 
the intervention were xanthosine, 3-hydroxyisovalerate, and 
dimethylglycine (Leal-Witt et al. 2018).
In the shorter intervention, Perez-Cornago et  al. 
(2014)  studied the effect of an energy-restricted diet 
(Table  2). The concentrations of SFAs, including pal-
mitic acid (C16:0) and stearic acid (C18:0), MUFAs (oleic 
acid (C18:1) and cis-11–eicosenoic acid (C20:1)), cis-11, 
14-eicosadienoic acid (C20:2), and cis-4, 7, 10, 13, 16, 
19-docosahexaenoic acid (C22:6n-3), and total, ω-6 and 
ω-3 PUFAs were significantly reduced, and isoleucine con-
centrations were decreased in serum after the intervention. 
Palmitoleic acid (C16:1) appeared to predict body fat loss 
negatively. Other short-term intervention showed signifi-
cantly higher increases in plasma of MCAC and long-chain 
AC (LCAC) and lysoPC (20:4) in overweight adults with 
a low-calorie diet than their control group (Table 2) (Kang 
et al. 2018). A study including MHO women undergoing a 
lifestyle weight loss treatment for 3 months (and a 12-month 
follow-up) showed an altered plasma metabolome (Almanza-
Aguilera et al. 2018). Namely, higher levels of formate and 
phosphocreatine and lower levels of trimethylamine were 
observed in the treatment group than in the control group. 
Moreover, higher myo-inositol, methylguanidine, and 
3-hydroxybutyrate levels and lower proline levels were also 
detected in the treatment group; higher levels of hippurate 
and asparagine and lower levels of 2-hydroxybutyrate and 
creatine correlated with weight loss. Nevertheless, these 
changes were statistically significant after three months 
follow-up, but not at the 12-month follow-up. In another 
study, MHO women followed a hypocaloric Mediterranean 
diet with physical activity recommendations for 12 months 
(Table 2) (Palau-Rodriguez et al. 2019). The relative con-
centration of 1,5-anhydroglucitol was increased in plasma 
in the low weight loss (LWL) group after the intervention. 
The plasmalogen 1-(1-enyl-palmitoyl)-2-oleoyl-sn-glyc-
ero-3-phosphocholine (P-16:0/18:1) and the exogenous 
compound carotenediol were increased in the high weight 
loss (HWL) group, and significantly more so than in the 
LWL. Then, the levels of 3-(4-hydroxyphenyl) lactate and 
some sphingolipids (SM (d18:0/22:0) and SM (d18/0/20:0, 
d16:0/22:0)) decreased more after the intervention in the 
HWL versus LWL. Similarly, the androgens 16α-hydroxy
dehydroepiandrosterone 3-sulfate and androstenediol (3β, 
17β) disulfate decreased in both weight loss categories, but 
a higher decline was observed in the HWL.
Using a different approach, Zheng et al. (2016a, b) ana-
lyzed urine, plasma, and fecal samples from individuals on 
an energy-restricted diet with either low or high-dairy intake 
for 24 weeks (Table 2). They reported increased levels of 
citrate, creatinine, and urea and decreased levels of hippu-
rate and TMAO after a high-dairy intake compared with a 
low intake. Furthermore, the plasma metabolome reflected 
a change in the lipid and lipoprotein profile associated with 
the energy restriction. The changes in the fecal metabolome 
(mainly short-chain FAs (SCFAs)) were related to dairy 
intake. Furthermore, in a large cohort of pregnant women 
with obesity diet and physical activity intervention during 
pregnancy and up to 6 months lessened the reduction in the 
proportion of ω-6 and PUFAs and reductions in the rate of 
increase in the proportion of saturated FAs (Table 2) (Mills 
et al. 2019) Rates of increase in lactate, pyruvate, and ala-
nine were reduced, and of acetate increased in comparison 
with the control group (Mills et al. 2019). Thereupon, the 
lifestyle intervention led to mitigating the metabolic changes 
during pregnancy that might be characteristic of obesity and 
pregnancy status.
Finally, Zheng et al. (2016b) analyzed data from the 
POUNDS LOST and the DIRECT studies (Table 2). Both 
cohorts followed a weight loss program with similar charac-
teristics and were followed for 2 years, including a 6-month 
visit. The POUND LOST study revealed correlations 
between decreased nine plasma levels of AAs (BCAAs (leu-
cine/isoleucine and valine), aromatic AAs (tyrosine and phe-
nylalanine), and finally alanine, proline, sarcosine, hydroxy-
proline, and methionine) with weight loss; moreover, the 
DIRECT study validated the correlations with seven of these 
AAs (alanine, tyrosine, leucine/isoleucine, sarcosine, phe-
nylalanine, hydroxyproline, and methionine). Additional 
analyses showed stronger correlations with these changes 
after 6 months, although the change persisted for 2 years.
Additionally, three interventions studied the effect of 
weight loss induced by physical activity. First, Meucci 
et al. (2017) reported that a four-week exercise program 
did not significantly change the metabolic signature of 
overweight preadolescents. Nevertheless, an eight-week 
program increased the urine concentrations of pantothenic 
acid, glyceric acid, l-ascorbic, xanthine, and adenosine 
compared to the control group (Meucci et al. 2017).Other 
intervention study assessed the effect of endurance training 
for 6 weeks on gut metagenome and plasma metabolites of 
overweight women (Table 2) (Munukka et al. 2018). The 
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training intervention decreased plasma phospholipids and 
cholesterol in large VLDL particles, with not more signifi-
cant alterations in any other plasma metabolites (including 
AAs, FAs, ketone bodies or gluconeogenesis-related metab-
olites) (Munukka et al. 2018). Likewise, no associations 
were studied between plasma metabolites and cardiovascular 
and inflammation biomarkers.
In a more extended intervention (Duft et al. 2017), three 
times/week for 24 weeks, including obese individuals in a 
combined training program, shifts in the serum levels of 20 
metabolites were observed. Of these metabolites, tyrosine, 
2-oxoisocaproate, histidine, and pyruvate appeared to be the 
best discriminators. Moreover, those metabolites were cor-
related with functional and biochemical parameters, such 
as strength, peak  VO2, the percentages of fat mass and lean 
body mass, WC, and plasma insulin concentration.
3.5  Dietary interventions focused on obesity 
and risk factors related to obesity
Four studies examined the effects of dietary interventions 
on obesity and obesity-related risk factors, such as inflam-
mation and oxidative stress (Table 3). Nieman et al. studied 
the plasma and serum metabolomes of overweight women 
who ingested a red pepper spice supplement (Nieman 
et al. 2012a, b) or chia seeds (Nieman 2012b) for four and 
10 weeks, respectively. The targeted analyses were focused 
on metabolites associated with inflammation and oxidative 
stress, but no significant changes were observed after the 
interventions.
Gu et al. (2013) studied the effect of a very low-car-
bohydrate diet (VLCD) on obese subjects (Table 3). The 
authors first identified the differences between obese and 
lean individuals. A serum profile comprised of increased 
levels of FAs, AAs, and carboxylic acids characterized the 
obese subjects. After consuming a VLCD for 8 weeks, the 
obese subjects exhibited several metabolic shifts in the levels 
of these metabolites. In parallel, specific alterations were 
also observed, including shifts in the arachidonate, cis-11, 
14-eicosadienoate, cis-11, 14, 17-eicosatrienoate, 2-amin-
obutyrate, AC and threonate concentrations, all of which are 
involved in inflammation and oxidation processes.
Kim et al. (2013) administered a 12-week black soybean 
peptide dietary intervention and identified key metabo-
lites associated with weight loss in healthy obese subjects 
(Table 3). After supplementation, the serum concentrations 
of metabolites such as betaine, benzoic acid, pyroglutamic 
acid, pipecolic acid, N-phenylacetamide, uric acid, l-aspar-
tyl-l-phenylalanine, and lysoPCs (lysoPC a C18:1, lysoPC a 
C18:2, lysoPC a C20:1, and lysoPC a C20:4) were increased. 
Meanwhile, the levels of l-proline, valine, l-leucine/isoleu-
cine, hypoxanthine, glutamine, l-methionine, phenylpyruvic 
acid, several carnitine derivatives, and lysoPCs (lysoPC a 
C14:0, lysoPC a C15:0, lysoPC a C16:0, lysoPC a C17:1, 
lysoPC a C18:0, and lysoPC a C22:0) were significantly 
decreased.
Recently, other authors have investigated the effect of 
Korean black raspberry (KBR) supplement for 4 weeks 
on overweight or obese individuals with a sedentary life-
style (Kim et al. 2017) to identify metabolites that predict 
responses to such intervention against oxidative stress and 
inflammation (Table 3). Increased levels of several urinary 
AAs, organic acids and other type of metabolites were as 
betaine, N-phenylacetylglycine and phenylacetate were 
observed. Moreover, the levels of adenosine and carnitine 
decreased after the intervention. Authors concluded that 
higher level of glycine and N-phenylacetylglycine (as a two-
metabolite set) had the most robust prognostic relevance for 
future interventions against oxidative stress.
Romo-Hualde et al. (2018) investigated the effects of 
eicosapentaenoic acid (EPA) and α-lipoic acid (α-LA) on 
urinary metabolomic profiles in overweight/obese women 
(Table 3).
The group supplemented with α-LA presented a weight 
loss that was associated with a highlighted presence of an 
ascorbate intermediate metabolite (one of the isomers of tri-
hydroxy-dioxohexanoate, or dihydroxy–oxohexanedionate).
In a postprandial study, the metabolic profile from obese 
adults with MetS showed a differential response to low-fat 
milk or a rice beverage consumption (Table 3) (Xu et al. 
2018). At 120 min, nine metabolites (i.e., orotate, leu-
cine/isoleucine, mesoxalate, asparagine, citrulline, methio-
nine, allantoin, ornithine, and tyrosine) were significantly 
altered in the low-fat milk versus the rice beverage group. 
The evaluation of a low-glycemic index diet in overweight/
obese adults for 6 months (Table 3) (Hernández-Alonso 
et al. 2019) revealed several changes. The plasma serine 
levels were significantly increased following the low gly-
cemic index diet compared to both the high glycemic index 
and low-fat diets. Tyrosine was decreased, and glycine was 
increased in the group receiving the low glycemic index 
diet versus that having the high glycemic index diet. Also, 
they observed a significant decrease in leucine and valine 
in the low glycemic index diet in contrast to the low-fat 
diet. Regarding lipids, several phosphatidylcholines (i.e., 
C32:1, C34:2e, C36:2e, C36:5e, C38:5 …) were signifi-
cantly reduced after the low glycemic index diet versus the 
high glycemic index and/or low-fat diets.
Hibberd et al. (2019) conducted an RCT to study the 
effects of a probiotic (Bifidobacterium animalis subsp. lac-
tis 420™) and/or a prebiotic (polydextrose) interventions 
in MHO subjects for 6 months (Table 3). Interestingly, the 
primary conjugated plasma bile acid, glycocholic acid, was 
reduced in the pre- and probiotic combination compared 
to placebo. In addition, secondary conjugated plasma bile 
acids were also reduced (Hibberd et al. 2019).
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Finally, an intervention that contained pea fiber did not 
cause changes in the serum metabolites of overweight/
obese adults after 12 weeks of consumption (Table 3) 
(Mayengbam et al. 2019). However, fecal SCFAs and bile 
acids were altered. For instance, acetate was significantly 
increased, and isovalerate decreased after pea fiber inter-
vention (but not compared to placebo). The concentrations 
of fecal primary cholic acid and chenodeoxycholic acid, 
and secondary deoxycholic bile acid and total bile acids 
were significantly reduced in the intervention group.
4  Discussion
The use of metabolomics to study obesity is increasing 
and improving our understanding of the alterations that 
occur during the development of obesity and their rela-
tionships with the disease. The results from the articles 
here included were categorized according to the different 
approaches reported. However, to facilitate the interpre-
tation, the discussion will be focused on the metabolite 
classes to understand the different alterations related to 
obesity. Hence, metabolites are grouped in sexual steroids, 
AA and protein metabolism, AC, lipids, carbohydrates, 
and other relevant molecules (not included in a specific 
group).
4.1  Metabolic features of obesity: characterization 
and importance of the metabolomics signature
Obesity is a whole-body adaptation to extra energy intake 
and decreased energy expenditure, mainly due to a seden-
tary lifestyle and a lack of physical activity. Also, obesity 
plays a crucial pathophysiological role in the development 
of IR, dyslipidemia and hypertension, leading to T2DM and 
an increased risk of CVD (Bastard et al. 2006; GBD 2015 
Obesity Collaborators et al. 2017; Williams et al. 2015). 
Therefore, the characterization of the metabolomic signature 
in obese subjects might aid researchers in identifying those 
subjects at a higher risk of developing metabolic diseases, 
thus facilitating the timely administration of an appropriate 
treatment strategy.
4.1.1  Sexual steroids
The identification of a metabolic signature associated with 
age might provide more efficient preventive treatments for 
obesity before individuals reach adulthood. Body compo-
sition during puberty has been suggested to be a predic-
tive marker of body composition in adulthood (Guo et al. 
2002), as well as predicting the risk of comorbidities such 
as obesity, dyslipidemia and CVD (Baker et al. 2007; Van-
dewalle et al. 2015). Accordingly, both puberty and sex hor-
mones have been shown to contribute to the development 
of obesity and CVD (Vandewalle et al. 2015; Widén et al. 
2012; Zhai et al. 2015). For instance, Butte et al. (2015) 
detected an association between DHEA-S and BMI and adi-
posity in obese children. Moreover, prepubertal obese males 
showed significantly higher serum levels of DHEA-S, but 
also of testosterone than normal-weight children (Reinehr 
et al. 2005). However, Gawlik et al. (2016), did not identify 
any urinary steroid signature correlated with BMI. Neverthe-
less, we should highlight that these authors did not compare 
the obesity profile with lean controls.
Interestingly, the 16α-hydroxydehydroepiandrosterone 
3-sulfate decreased after LWL, and even a more signifi-
cant reduction was observed after HWL in MHO women 
(Palau-Rodriguez et al. 2019). These findings might reflect 
the modulation of endocrine metabolism due to weight loss. 
Accordingly, steroid sulfation and desulfation are fundamen-
tal pathways for endocrine balance, specifically for fat mass 
distribution and glucose metabolism (Mueller et al. 2015). 
Actually, DHEA-S is one of the most abundant steroids in 
human circulation and accumulate in AT at even higher con-
centrations (Bélanger et al. 2006). Furthermore, although 
the authors claimed that the steroid derivative, 12-ketopor-
rigenin, was also positively correlated with BMI (Zhao et al. 
2016a, b), we should highlight that such a compound origin 
is related to the consumption of onion-family vegetables 
(Fattorusso et al. 2000) and such a finding should be care-
fully interpreted.
Nonetheless, the role of sexual steroids in obesity may 
differ at various life stages and with sexual dimorphism. 
For example, testosterone, the most critical androgen for 
males, has been described to be anti-adipogenic; its supple-
mentation in adult men reduces abdominal fat by stimulat-
ing lipolysis and thereby reducing fat storage in adipocytes 
(Vitale et al. 2010). Even during pubertal development, 
lower testosterone concentrations have been observed in 
obese boys than in normal-weight boys (Mogri et al. 2013; 
Taneli et al. 2010). In addition, a consistent inverse correla-
tion between testosterone levels and markers of adiposity in 
overweight adult males has been detected (Bann et al. 2015; 
Blouin et al. 2005; Gagnon et al. 2018; Gates et al. 2013; He 
et al. 2018). However, the data are less uniform in females, 
with no association (He et al. 2018) or a positive correla-
tion observed in overweight-obese women (Bann et al. 2015; 
De Simone et al. 2001) and an inverse correlation observed 
in non-obese postmenopausal women (Casson et al. 2010). 
However, DHEA-S appears to play a more significant role 
in women body composition, both in young females (De 
Simone et al. 2001; Mäntyselkä et al. 2018) and in adult ones 
(Barrett-Connor and Ferrara 1996; De Pergola et al. 1994). 
The androgen receptor is expressed widely throughout the 
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AT compartment, indicating that white AT adipocytes may 
be particularly sensitive to androgens (Newell-Fugate 2017). 
Hence, it is consistent with the findings reported by Palau-
Rodriguez et al. (2019) in relation to the weight loss effect 
on steroid sulfates. Therefore, more studies focused on deter-
mining the roles of steroids in obesity are necessary, particu-
larly from a metabolomics perspective.
4.1.2  AA and protein metabolism
One of the major groups of metabolites dysregulated in obe-
sity is AAs, particularly BCAAs and AAAs. Phenylalanine 
concentrations were higher in obese individuals (Butte et al. 
2015; Kim et al. 2010b; Fattuoni et al. 2018; Wang et al. 
2018; Houttu et al. 2018; Yu et al. 2018). Moreover, tyrosine 
levels, a hydroxylation product of phenylalanine metabo-
lism, have been associated with an increase in the hepatic fat 
content (Haufe et al. 2016), and its levels (as well as alanine) 
have been associated with prediction of successful weight 
loss (Stroeve et al. 2016) and weight loss per se following 
dietary and physical activity interventions (Duft et al. 2017; 
Geidenstam et al. 2017a; Zheng et al. 2016a, b). Further-
more, tyrosine contributes significantly to the profile defined 
in obese children and could serve as a posible predictor of IR 
in obese children (Hellmuth et al. 2016; Butte et al. 2015). 
In addition, p-cresol and p-cresol sulfate, degradation prod-
ucts of tyrosine and to some extent of the phenylalanine 
metabolism and phenylacetamide (an intermediate) were 
increased in plasma (Yu et al. 2018). Therefore, modifica-
tions in the phenylalanine and tyrosine metabolism might 
be a result of liver dysfunction associated with metabolic 
derangement (Libert et al. 2018). Further investigation is 
needed to determine if the study of the tyrosine metabolism 
could serve to identify the metabolic wellness of overweight 
and obese people.
Higher concentrations of tryptophan and its metabo-
lites, kynurenine and kynurenic acid, have been detected 
in obese subjects and are associated with BMI (Yu et al. 
2018; Ho et al. 2016; Zhao et al. 2016a, b; Carayol et al. 
2017). Interestingly, alterations in the kynurenine pathway 
have been reported in subjects with obesity and IR (Faven-
nec et al. 2015), and furthermore, increased levels of both 
metabolites have been detected in patients with diabetic 
retinopathy (Munipally et al. 2011). The higher levels of 
such compounds might reflect immune activation or low-
grade systemic inflammation due to an increase in the 
enzyme indoleamine 2,3-dioxygenase (IDO) activity (Zhao 
et al. 2016a, b; Dadvar et al. 2018). The increased activ-
ity of IDO has been closely related to the propagation of 
obesity, probably, because the reduced tryptophan mediated 
by IDO may reduce serotonin production and cause mood 
disturbances, depression, and impaired satiety ultimately 
leading to increased caloric uptake and obesity (Brandacher 
et al. 2007). In contrast, decreased glycine levels have been 
detected urine, plasma and skeletal muscle samples from 
obese subjects and are inversely correlated with BMI (Baker 
et al. 2015; Butte et al. 2015; Cho et al. 2017; Kraus et al. 
2016; Newgard et al. 2009). Although little is known about 
the pathophysiological mechanisms associated with glycine 
depletion, glycine utilization in patients with diabetes is 
increased because of excess acyl group formation (Adeva-
Andany et al. 2018).
Several studies in animal models support a close asso-
ciation between obesity state and plasma (She et al. 2007; 
Sailer et al. 2013) and urine citrulline levels (Connor et al. 
2010), indicating impairment of the hepatic amino acid 
handling. A possible hypothesis suggested is regarding the 
changes of AAs involved in the urea cycle in obesity, that 
could indicate in turn an alteration of urea synthesis in the 
liver, i.e., a block in the cytosolic reactions with increased 
ornithine and citrulline levels (She et al. 2007) and there-
fore a reduced systemic arginine bioavailability (decreased 
ratio of plasma arginine to ornithine + citrulline) (Tang et al. 
2009; Sailer et al. 2013). HFD mice presented a reduction of 
arginine levels, while citrulline levels were elevated (Sailer 
et al. 2013). However, metabolomics findings in human 
studies have demonstrated the opposite. For instance, an 
inverse association of human plasma citrulline with BMI 
was observed by Ho et al. (2016) and lower citrulline con-
centrations were observed in the skeletal muscle of obese 
subjects compared with lean controls (Baker et al. 2015). 
Furthermore, the citrulline levels (along with other AAs 
such as leucine/isoleucine, mesoxalate, asparagine, methio-
nine, allantoin, ornithine, and tyrosine) were higher at post-
prandial measurement in the low-fat trial compared to the 
rice milk in obese population with MetS, probably because 
of the higher protein content of low-fat milk (Xu et al. 2018). 
Although unaltered levels of serum citrulline in obese sub-
jects have been reported (Newgard et al. 2009), the most 
common finding is to encounter this compound decreased 
in obese subjects and in patients with diabetes (Park et al. 
2015). Nevertheless, the physiological cause that might 
explain this inverse association is still unknown, although 
it might be related to the degree of liver steatosis, which is 
usually present in the obese state.
Uric acid levels are substantially increased in obese sub-
jects and proportionally associated with BMI (Park et al. 
2015; Ho et al. 2016; Ruebel et al. 2019) and recently associ-
ated with BMI (Cirulli et al. 2019). Additionally, it has been 
revealed that hyperuricemia is a predictor of IR and T2D 
debut (Gil-Campos et al. 2009; Krishnan et al. 2012). Hyper-
uricemia may also cause obesity by accelerating hepatic and 
peripheral lipogenesis (Johnson et al. 2011) and could also 
reflect high oxidative stress as it is known as an antioxidant 
and scavenger of free radicals.
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On the other hand, the characteristic increased exog-
enous consumption of proteins and therefore endogenous 
production of uric acid due to the purine catabolism in the 
obese population are additional factors that result in hyper-
uricemia (Remedios et al. 2012). Hence, the evidence for 
increased uric acid levels in obese individuals is widely 
known, although its change in response to dietary interven-
tions should be studied with a more exhaustive design and 
statistical adjustments; Kim et al. (2013) reported increased 
uric acid levels after the administration of the black soybean 
peptide supplement to overweight/obese subjects with a sub-
sequent weight and body fat loss. This unexpected finding 
was not discussed and probably the change of dietary habits 
because of the soybean intervention might influence on the 
unadjusted data for protein consumption.
Regarding BCAAs, associations between elevated serum 
concentrations with obesity, IR, and other complications 
were observed several decades ago (Felig et al. 1969; New-
gard et al. 2009). In fact, many studies have described higher 
blood levels of BCAAs both in obese children (Butte et al. 
2015) and adults (Kim et al. 2010b; Newgard et al. 2009; 
Xie et al. 2014; Wang et al. 2018) and positive correlations 
with anthropometric markers and fat mass (Foerster et al. 
2015). Stroeve et al. (2016) detected higher concentrations 
of BCAAs in MO women than in obese women. By con-
trary, decreased levels of BCAAs have been associated with 
weight loss in obese subjects (Geidenstam et al. 2017a), 
after weight loss through diet (Kim et al. 2013; Zheng et al. 
2016b; Hernández-Alonso et al. 2019) or physical activ-
ity in pregnant women (Mills et al. 2019). The increase, or 
decrease during weight loss, of BCAAs, reflect the status 
of the protein breakdown, which is a consequence of IR, 
thus pointing towards to metabolic complications. In fact, 
the higher concentrations of glutamate observed in six stud-
ies (Butte et al. 2015; Newgard et al. 2009; Yu et al. 2018; 
Maltais-Payette et al. 2018; Wang et al. 2018; Carayol et al. 
2017) might be linked to the BCAAs alterations, since such 
an AA is produced as the first step of BCAAs catabolism 
(Newgard 2017).
Elevated concentrations of ADMA in obese subjects (Cho 
et al. 2017; Feldman et al. 2019; Butte et al. 2015) is associ-
ated with endothelial dysfunction, most probably due to the 
reduction of arginine availability (Eid et al. 2004; El Assar 
et al. 2016). Interestingly, such findings are reported in ado-
lescents and adult subjects, and it would be of keen interest 
to investigate in-depth if this compound might serve as a 
marker of severity of endothelial dysfunction.
Furthermore, specific intermediate metabolites of AAs 
have been reported to be important markers of obesity and 
its complications (Newgard et al. 2009). For instance, lower 
levels of α-KIC, a metabolite derived from leucine, were 
detected in the subcutaneous AT of obese subjects (Hanzu 
et al. 2014), along with diminished leucine uptake in the 
obese visceral fat depots. The dysregulation of leucine 
metabolism seems to be increased in the visceral obese AT, 
preventing the formation of α-KIC. Moreover, catabolic 
pathways of leucine through the KIC acid route involve 
the formation of substantial amounts of alanine and glu-
tamine. These pathways are the route for the disposal of 
amino groups released from the transamination of BCAAs 
(Newgard et al. 2009). Therefore, as alanine and glutamine 
are highly gluconeogenic AAs, a possible hypothesis is that 
the increased amount of alanine released by the visceral AT 
to the systemic circulation contributes to hyperinsulinemia 
and the development of IR.
4.1.3  Acylcarnitines
AC are organic compounds containing an FA, with the car-
boxylic acid attached to carnitine through an ester bond. 
The roles of fatty AC species reflect different situations in 
the organism. Increased levels of SCAC species indicate 
amino acid anaplerosis; medium-chain species reflect distal 
β-oxidation (i.e., downstream of CPT-1) whereas long-chain 
species reflect transport and proximal β-oxidation efficiency 
(i.e., including an upstream of CPT-1). The sentinel spe-
cies C6, C8, C10, and C10:1 have been used to evaluate the 
MCAC flux through the β-oxidation pathway (Baker et al. 
2015). Hence, AC might serve as relevant biomarkers of IR 
and are defined as a by-product of fat and amino acid oxida-
tion in mitochondria (Makrecka-Kuka et al. 2017). Obese 
subjects have shown a high rate of incomplete FA oxidation, 
abnormal AC profiles, and AAs biosynthesis, along with 
the perturbation of mitochondrial metabolites (Schoone-
man et al. 2013). In obese children, the levels of several 
SCAC, such as C5-OH, C3, C4 (Butte et al. 2015), C12:1 
and C16:1 (Wahl et al. 2012), are elevated. A higher C3 
level was also detected in obese men (Baker et al. 2015; Xie 
et al. 2014; Piening et al. 2018), as well as higher C4/4i, C5, 
and C5:1 levels (Baker et al. 2015; Cirulli et al. 2019; Pien-
ing et al. 2018). Moreover, obese subjects exhibit increased 
concentrations of C4/4i, C6, C8, C10:1, and C10:2 in skel-
etal muscle AC, and C3 and C4/4i in plasma in response 
to the HFD challenge compared with lean subjects (Baker 
et al. 2015). Overall, the observed accumulation of BCAAs 
in the flux increases its catabolism in the liver and skeletal 
muscle. As a result, the elevated concentration of BCAAs 
may hypothetically be associated with the higher concen-
trations of the SCACs C3 and C5 as C3 AC reflects the 
propionyl CoA pool; propionyl CoA is a by-product of 
both isoleucine, and valine catabolism and C5 AC are com-
prised of α-methylbutyryl and isovalerylcarnitine species; 
α- methylbutyryl CoA and isovaleryl CoA are intermediates 
in mitochondrial isoleucine, and leucine catabolism, respec-
tively, and these intermediates equilibrate with their cognate 
AC esters (Newgard et al. 2009; Schooneman et al. 2013; 
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Feldman et al. 2019). Whereas C4 can be produced in both 
amino acid and fatty acid catabolism (Koves et al. 2008).
Remarkably, Kang et al. (2018) observed increases in 
plasma MCAC AND LCAC in overweight adults with a 
low-calorie diet and these changes were negatively corre-
lated with changes in visceral fat areas (Kang et al. 2018). 
Such findings could be explained as increased oxidation of 
the free FAs (FFA) released from the visceral fat due to the 
weight loss, thus generating MCAC and LCAC. Then, the 
increase of MCAC and LCAC levels may be driven by an 
improvement of the acetyltransferase activity rather than an 
unbalanced mitochondrial fatty acid oxidation (Schooneman 
et al. 2016; Kang et al. 2018).
4.1.4  Lipid metabolism
Lipids have diverse roles as signaling molecules, metabolic 
substrates, and cellular membrane components. The chain 
length and the degree of desaturation of the FA moieties in 
lipid molecules increase the complexity of biological roles 
assigned to various lipid classes. Moreover, lipids that are 
synthesized endogenously or obtained through diet exhibit 
differences in accumulation and/or metabolism and subse-
quent biological roles (Yang et al. 2018).
In the current study, we reported diverse findings from 
various studies, namely, changes in FAs, such as PUFAs 
and SFAs, as well as more complex lipids, such as sentinel 
lysophospholipids and sphingomyelins.
Houttu et al. (2018) identified a lipid signature in obese 
pregnant women characterized by high VLDL subclasses 
and lower HDL particles and other PUFAs. Furthermore, 
according to Mills et al. (2019), obese pregnant women 
following a lifestyle intervention reduced their ω-6 and 
total PUFAs. Such a profile should be related to lifestyle 
and diet rather than a consequence of obesity. Remarkably, 
the study of the placenta from obese women revealed a 
lipid profile that suggested a disruption of the LCPUFA 
biomagnification that might impact in the risk of adverse 
fetal outcomes and of the development of metabolic dis-
eases throughout postnatal life (Fattuoni et al. 2018). In 
fact, this is corroborated in the study from Sorrow et al. 
(2019) in which the presence of elevated lipid species, 
including linoleate, myristate, oleate, palmitate, stearate, 
caprate, and species of AC in the umbilical cord was asso-
ciated with the development of obesity at 3 to 5 years of 
age (Sorrow et al. 2019).
The serum concentrations of SFAs, including C16:0 and 
C18:0, and MUFAs (C18:1 and C20:1), and total, ω-6, and 
ω-3 PUFAs were decreased after the weight loss interven-
tion in the study by Perez-Cornago et al. (2014). Moreo-
ver, C16:1 was suggested to serve as a negative predictor 
of body fat loss. Concretely, SFAs are positively correlated 
with the development of obesity and diabetes, increasing 
complications related to metabolic disease (Jakobsen et al. 
2009; Kien et al. 2013).
Controversial findings related to lysoPC have been 
reported. Some authors have reported decreased levels of 
these compounds (Barber et al. 2012; Heimerl et al. 2014; 
Cirulli et al. 2019), whereas other evidence suggests a corre-
lation between plasma levels of lysoPC, sphingomyelins and 
phosphatidylcholines with obesity, although the pathways 
are not yet completely understood (Rauschert et al. 2016) but 
is hypothesized that such perturbations are a consequence 
of changes in weight rather than being a contributing factor.
Furthermore, phospholipids are also a group that charac-
terizes the obesity profile. Indeed, obese mice treated with 
PC 18:0/18:1 (1-Octadecanoyl-2-(9Z)-octadecenoyl-sn-glyc-
ero-3-phosphocholine) exhibited increased glucose tolerance 
and IS (Liu et al. 2013). Numerous studies reported in the 
current review have described profiles of several phospholip-
ids. For instance, Piening et al. (2018) detected a signature 
associated with BMI, which included several lysophospho-
lipids and that respond to fluctuations in the BMI. This was 
suggested to be related to a decrease in the catabolism due 
to increased caloric intake.
Higher lysoPC a C18:0 concentrations have been iden-
tified in urine samples from obese adolescents (Cho et al. 
2017) and in plasma samples from overweight/obese men 
(Kim et al. 2010b). Interestingly, after a black soybean pep-
tide intervention for 12 weeks, the levels of this lysoPC spe-
cies were decreased (Kim et al. 2013) and MHO showed 
lower levels than MUHO subjects (Bagheri et al. 2018). A 
similar phenomenon was detected for lysoPC a C14:0 in the 
same dietary intervention study (Kim et al. 2013).
Moreover, the lifestyle intervention by Mills et al. (2019) 
in obese pregnant women, resulted in a decrement in the rate 
of increase of phospholipids along with triacylglycerols in 
extremely large, very large, large and medium VLDL parti-
cles (Mills et al. 2019).
In contrast, decreased lysoPC a C18:1 and C18:2 were 
detected in obese children and adults (Wahl et al. 2012; Kim 
et al. 2010b), and both compounds were inversely associated 
with BMI (Bagheri et al. 2018). Whereas, an increase was 
observed after a black soybean intake (Kim et al. 2013). 
Moreover, significantly lower plasma lysoPC a C18:2 levels 
were observed in MO men and women than in obese subjects 
(Stroeve et al. 2016). In a young population, the PC a C34:1 
and C34:2 levels are decreased in obese individuals (Cho 
et al. 2017; Wahl et al. 2012). While lower PC a 20:4 levels 
were only observed in obese children (Wahl et al. 2012). 
Nevertheless, the levels of these three lipids increased in 
obese adults after the black soybean peptide intervention 
(Kim et al. 2013). Overall, the presented evidence points 
towards an association of phospholipids with a diet mainly 
high-fat composed and might be regulated through the addi-
tion of fiber-contained products.
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Differences in the levels of other phosphatidylcholines, 
such as PC a C34:4, PC a C38:5, and PC a C38:6, sphin-
gomyelins and hydroxysphingomyelins, such as SM C16:0 
or SM (OH) C22:1, PC ae (C38:7), PC ae (C40:6), PC ae 
(C38:3), and PC ae (C40:4) between healthy and obese sub-
jects have been observed in some studies, but not in other 
studies, and thus these molecules are not considered critical 
metabolites in obesity signatures or as markers of weight 
loss.
Overall, the role of these lipid species remains to be 
investigated in-depth in humans. Nevertheless, some find-
ings are consistent and might at least partially explain the 
physiopathology of obesity and the associated everyday hab-
its, such as high-fat intake. For instance, higher saturated 
fat intake with a lower ratio of PUFAs/SFAs and relatively 
lower carbohydrate levels in overweight/obese than in lean 
subjects might partially explain the higher levels of lysoPC a 
C18:0 (Kim et al. 2010b, 2014). The hypothesis that the FA 
composition of serum (lyso-) phospholipids partially reflects 
an individual’s medium-term dietary FA intake has already 
been supported (Hodge et al. 2007).
4.1.5  Carbohydrates
Carbohydrate metabolism is vital for all metabolic pro-
cesses, and its roles in the development and maintenance 
of obesity have been a matter of debate for decades. Glu-
cose is catabolized via glycolysis to pyruvate, which is con-
verted into acetyl coenzyme A (CoA), the entry point into 
the TCA cycle, under aerobic conditions (Park et al. 2015). 
Xylitol may be used as a substrate in the pentose phosphate 
pathway to produce fructose-6-phosphate that can generate 
acetyl CoA, a primary substrate for the TCA cycle, via gly-
colysis. Most likely, because of its implication in the TCA 
cycle, xylitol has been investigated in some studies. A lower 
baseline concentration of xylitol predicted a more significant 
decrease in BMI and ≥ 10% weight loss in subjects after 
a 1-year weight loss program (Geidenstam et al. 2017a). 
Human metabolism of xylitol, as well as its absorption from 
food (Islam and Indrajit 2012) or potential involvement of 
the gut microbiota, is not well understood. A study in mice 
detected significant changes in the microbiota following 
daily dietary supplementation with xylitol; the abundance 
of the phylum Firmicutes was increased in the group fed an 
HFD with xylitol solution (Park et al. 2015). The phylum 
Firmicutes accelerates the degradation of food components 
to supply energy to the host, and therefore is considered an 
obesity-related bacterial phylum (Khan et al. 2016).
Interestingly, 1,5 anhydroglucitol, a monosaccharide 
found almost in all foods, has been proposed as a biomarker 
of short-term glycemic control, for screening undetected 
T2D in saliva (Mook-Kanamori et al. 2014) and associations 
with BMI and adiposity indicators have been shown (Lipsky 
et al. 2016). In fact, a reduction after a lifestyle interven-
tion in women and reported positive associations of such 
a compound with weight variables has been found (Palau-
Rodriguez et al. 2019).
Mannose is one of the most common glucose metabolites 
reported in the current SR at incremented levels, both in 
obese adults (Fiehn et al. 2010; Gogna et al. 2015; Moore 
et al. 2013; Park et al. 2015) and in obese children (Butte 
et al. 2015). The liver is the main organ for mannose con-
sumption; thus, an abnormal utilization will reflect higher 
concentrations in plasma. It is hypothesized that mannose 
may play a role in the development of IR, as it will reflect 
defective glycosylation that could also affect the insulin 
receptors in the liver tissue (Lee et al. 2016).
In this context, targeted metabolomics research that 
includes an analysis of glucose metabolites in obese and lean 
individuals will provide comprehensive information about 
their contributions to the metabolic signature of obesity and 
facilitate a determination of whether these metabolites might 
be targets for obesity treatments.
4.1.6  Other relevant molecules
Other molecules reported in the literature have controver-
sial roles, such as the nucleoside, adenosine. Although no 
evidence has suggested a possible correlation between the 
levels of this nucleoside and the obesity signature, polyphe-
nol supplementation in overweight or obese adults decreases 
the plasma adenosine levels (Kim et al. 2017). In contrast, 
a physical activity program increased urinary adenosine 
concentrations in overweight preadolescents (Meucci et al. 
2017). The role of adenosine in obesity is not clear, since it 
not only participates in the obesity but is also involved in the 
initiation of obesity, and it may have anti-obesity activities 
as well (Pardo et al. 2017). Adenosine promotes adipogen-
esis by activating the A1 receptor and inhibits adipogenesis 
mediated by the activation of the A2B receptor in preadipo-
cytes (Gharibi et al. 2012). In this context, adenosine exerts 
a receptor- and tissue-dependent effect. For example, adeno-
sine receptor activation impairs insulin action in skeletal 
muscle (Pardo et al. 2017).
2-Ketoglutarate, also known as α-ketoglutarate or 2-oxo-
glutarate, is a key intermediate metabolite of one of the most 
fundamental biochemical pathways in carbon metabolism, 
the TCA. According to a study in mice, the administration of 
α-ketoglutarate might affect body weight and innate intesti-
nal immunity by influencing the intestinal microbiota (Chen 
et al. 2017). Also, α-ketoglutarate has been associated with 
the induction of skeletal muscle hypertrophy and inhibition 
of protein degradation. In obese subjects, urine and skel-
etal muscle were decreased (Newgard et al. 2009; Baker 
et al. 2015), despite a targeted approach revealed positive 
correlations with BMI abdominal obesity, HOMA-IR and 
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triacylglycerol levels (Ho et al. 2016). Therefore, further 
studies should focus on the role of this compound and its 
relationships with obesity, protein degradation, hypotrophy, 
and the intestinal microbiota.
In urine, serotonin levels were observed lower in young 
obese than normal-weight subjects (Cho et al. 2017). In the 
central nervous system, serotonin is intricately involved 
in appetite and subsequent nutrient intake (Tecott 2007), 
primarily regulated by processes innervated in the hypo-
thalamus (Yabut et al. 2019). In fact, the inhibitory effect 
of serotonin on appetite has led to the approval of receptor 
agonists for the treatment of obesity (Bohula et al. 2018; 
Fidler et al. 2011; O’Neil et al. 2012; Smith et al. 2010) or 
even treatments based on the serotonin precursor 5-HTP that 
are involved in the meal satiation and the end state of post-
meal satiety (Halford et al. 2005).
TMAO has been reported as biomarker of obesity (Zheng 
et al. 2016a, b), CVD risk (Bennett et al. 2013; Trøseid et al. 
2015) and it is originated from microbial activity (Leal-Witt 
et al. 2018; Zheng et al. 2016a, b). Its precursor trimethyl-
amine (TMA) provided from the microbial metabolism of 
dietary carnitine and choline, decreased in weight loss con-
ditions (Almanza-Aguilera et al. 2018). TMA is oxidized by 
hepatic flavin-containing monooxygenases to form TMAO, 
which has been shown to be both proatherogenic and asso-
ciated with CVD (Tang et al. 2013; Wang et al. 2011). 
Almanza-Aguilera et al. (2018) reported that lower levels 
of TMA after weight loss associated to lifestyle intervention 
are related to either a lower intake of its dietary precursors 
(i.e., eggs and meat) (Koeth et al. 2013; Tang et al. 2013) 
or modulation of choline and carnitine metabolism. Simi-
larly, TMAO was reduced in urine after a lifestyle interven-
tion program in obese prepubertal children (Leal-Witt et al. 
2018). Although cholesterol levels in these children were 
within the average values, the authors detected a positive 
association between the changes in TMAO and cholesterol 
levels. Additionally, TMAO decreases expression of two key 
enzymes, CYP7A1 and CYP27A1, essential for bile acid 
biosynthesis and multiple bile acid transporters (OATP1, 
OATP4, MRP2, and NTCP) in the liver, which decreases 
bile acid pool, resulting in decreased reverse cholesterol 
efflux (Koeth et al. 2013). In this context, the primary con-
jugated plasma bile acid, glycocholic acid along with sec-
ondary conjugated plasma bile acids (glycoursodeoxycholic 
acid, taurohyodeoxycholic acid, and tauroursodeoxycholic 
acid) were reduced in the pre- and probiotic combination 
compared to placebo after 6 months (Hibberd et al. 2019). In 
feces, the primary bile acids, cholic acid, and chenodeoxy-
cholic acid, the secondary deoxycholic acid and overall total 
bile acids were reduced after 12 weeks of pea fiber consump-
tion (Mayengbam et al. 2019). It is known that bile acids 
are synthesized from cholesterol and excreted through the 
feces (Ma and Patti 2014). Thereupon, as fiber (especially 
insoluble fiber) increases fecal mass, a dilution of bile acids 
content might be expected (Woodbury and Kern 1971).
4.2  Obesity as a risk factor for other metabolic 
comorbidities
Obesity is a risk factor for the development of several 
metabolic disorders. In fact, many authors reported meta-
bolic alterations, such as IR, related to obesity or weight. 
For instance, decreased decrease in the uptake of BCAAs 
in obese subjects (21) might explain the accumulation of 
these metabolites in the bloodstream and the subsequent pro-
gressive obesity-associated complications. Hence, elevated 
BCAA concentrations may also serve as a biomarker for an 
increased risk of metabolic syndrome (Iwasa et al. 2015; 
Newgard et al. 2009; Shah et al. 2010). For example, Badoud 
et al. (2015b) reported correlations between the levels of 
BCAAs (and FAs) with glucose levels and insulin AUC, 
Xie et al. (Xie et al. 2014) reported a correlation with IR 
and Haufe et al. (2016) reported a correlation with hepatic 
IR. Furthermore, negative correlations between whole-
body IS (calculated using the composite insulin-sensitivity 
index (C-ISI)) with plasma BCAA concentrations have 
been reported (Haufe et al. 2016). Similarly, Tulipani et al. 
(2016a, b) reported a positive correlation between valine lev-
els and the degree of IR, independent from the BMI. Gluta-
mate levels showed positive correlations with fasting insulin 
levels and the HOMA-IR index, while glycine concentra-
tions were negatively correlated with the same parameters.
Ketone bodies, such as α-hydroxybutyrate, are increased 
in obese children plasma (Butte et al. 2015) and have been 
identified as strongly associated with the obese and diabetic 
state (Fiehn et al. 2010; Gall et al. 2010; Stroeve et al. 2016). 
Interestingly, α-hydroxybutyrate has been investigated as an 
early marker of both IR and impaired glucose regulation in 
a nondiabetic population (Gall et al. 2010). Furthermore, 
the ketone body β-hydroxybutyrate was highly elevated in 
the skeletal muscle of obese men (more than in lean) during 
prolonged fasting (up to 72 h) (Bak et al. 2018). The greater 
increment of ketone bodies in obesity status might be the 
result of the increased catabolism of more available BCAAs, 
but increased metabolization of intracellular skeletal fat 
mass could also contribute to the increased production of 
ketone bodies. Hence, all the findings regarding the impli-
cations of several metabolites on IR progression in obese 
subjects might elucidate the relevance of metabolomics to 
explain the obesity-associated complications.
A hypothesis proposed to explain the development of IR 
in obesity is focused on the lipotoxicity. This hypothesis 
states that an oversupply of fats that exceed the capacity of 
adipocytes leads to storage in other tissues. Consequently, 
these cells produce bioactive lipids that reduce IS and fat 
flow into the cell (Rauschert et  al. 2016). LysoPCs are 
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derived from PCs during LDL oxidation via either the leci-
thin-cholesterol acyltransferase (LCAT) or the lipoprotein-
associated phospholipase A2 (LpPLA2) pathway. In fact, 
LpPLA2 activity has been reported to be increased in obese 
children. As a significant component of oxidized LDL, satu-
rated lysoPCs exert pro-atherogenic and pro-inflammatory 
effects and impair insulin signaling (Murugesan 2003; Wahl 
et al. 2012). Consistent with these findings, Rauschert et al. 
(2016). observed a significant correlation between increased 
lysoPC a C14:0 levels with a high HOMA-IR in normal-
weight young adults.
Thus, the current controversy regarding the causative 
role of and mechanisms underlying the effects of specific 
lipid classes on the subsequent development of IR in obese 
subjects is not surprising. However, new high-resolution 
metabolomics techniques have enabled the identification of 
lipid subclasses, and novel families of lipids that might even 
regulate IS, such as FA esters of hydroxy FAs (FAHFAs), 
diacylglycerols (DAG) and ceramides (Yang et al. 2018).
4.3  Metabolic challenges
The knowledge acquired through metabolomics in metabolic 
challenges is fundamental due to the real-time data obtained 
that reflects the dynamics of the human metabolome. A 
standard definition of metabolomics is that it provides “a 
snapshot” of the metabolism; however, in some situations, 
such as in patients with a particular disease, researchers must 
understand the dynamics and obtain a “motion picture” of 
the events occurring in the metabolism. For example, Gei-
denstam et al. (2014) first studied the differential response 
of lean and obese subjects to an OGTT and reported evi-
dent disruptions in the regulation of ketogenesis, lipolysis, 
and proteolysis in the obese individuals. Afterward, the aim 
was to study the response of an overweight/obese popula-
tion to an OGTT after weight loss and a weight maintenance 
period. As expected, the response differed between obese 
glucose-intolerant individuals and lean glucose-tolerant sub-
jects (Geidenstam et al. 2014). Most likely, the most exciting 
result is that those changes occurred in a temporally different 
manner that coincides with improvements in either hepatic 
or peripheral IS during weight loss and weight maintenance, 
respectively (Geidenstam et al. 2017a).
Badoud et al. (2015b) concluded that FAs, such as 14:0 
and 16:0 should serve as distinct markers of fasting and/or 
postprandial IS whereas SFA 18:0 can be inversely related to 
the fasting glucose levels. Interestingly, shorter chain SFAs 
were previously linked with an unhealthy cardiometabolic 
profile compared to longer chain SFAs (18:0, 22:0 and 24:0) 
(Badoud et al. 2015b). Subsequently, 18:0 SFA and ω-6 
PUFA were inversely correlated with fasting glucose levels 
in adults, regardless of the BMI (Badoud et al. 2015b). Fur-
thermore, MHO individuals showed better adaptability to the 
caloric challenge when compared to the MUHO individuals 
as the former preserved the IS. These findings are relevant 
if replicated in larger cohorts, in the translation to potential 
diagnostic use. We should note that recently, Bagheri et al. 
(2018) could identify differences between MHO and MUHO 
phenotypes when compared with normal-weight subjects but 
not when compared among them. Although their analysis 
had broad coverage, their reported metabolic signatures did 
not include any of the compounds reported by Badoud et al. 
(2015b).
Moreover, Baker et al. (2015) performed a 5-day HFD 
intervention that altered the metabolism of AC species, and 
its relationship with limited β-oxidation has already been 
discussed.
Bak et al. (2018) detected FFAs (palmitate, stearate, and 
arachidate) lower during 12 h of fasting in obese versus lean 
subjects. In addition, free carnitine that sustains the FFAs 
transportation into the mitochondria was lower in obese than 
lean participants. This phenomenon could indicate that there 
is a lower rate of release of FFAs during fasting in obese 
subjects that even might facilitate the insulin response at 
short-term in such population. Nevertheless, the regulatory 
mechanism of FFAs in context with insulin actions requires 
more detailed studies and to consider cautiously the pro-
cesses of fasting condition that could result controversial 
in humans.
4.4  Future perspectives
As shown in the present review, metabolomics studies facili-
tate the identification of metabolites involved in obesity by 
observing variations in metabolite concentrations in obese/
overweight subjects compared with healthy individuals. 
Additionally, metabolomics has been used to discover bio-
markers for several clinical conditions (Vinayavekhin et al. 
2010). Biomarkers are regularly used in clinical practice to 
measure disease severity and provide essential prognostic 
information related to survival (Park et al. 2015). Using 
metabolomics studies, the clinical practice and the studies 
of obese subjects might be more productive and focused on 
specific metabolites and critical pathways to treat or even 
prevent the development of obesity and its severe complica-
tions. Furthermore, an understanding of the metabolic sig-
nature of obesity and its dynamics should lead to elaborate 
subclassifications within obese patients, according to their 
metabolic characteristics. These profiles would help clini-
cians to either screen individuals or identify and character-
ize outliers in clinical trials designed to test solutions for 
obesity. In this regard, a very comprehensive guide for help-
ing in the developing of future nutrimetabolomics studies 
is presented by Ulaszewska et al. (2019) and must serve to 
harmonize the field.
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Significant findings are presented in this review and sug-
gest that several tracks should be followed. Moreover, more 
targeted and well-designed studies should focus on com-
pounds such as BCAAs, AC species, and phospholipids. 
Their pathways must be delineated, and in-depth studies of 
not only the metabolites but also the catabolites and come-
tabolites should be performed to understand their relevance.
Currently, the study of the microbiome is gaining impor-
tance, and researchers have hypothesized a link between 
obesity and the microbiome. Nevertheless, an integrative 
approach, including metabolomics, might improve our 
understanding that not only the variability but also the func-
tion of the microbiome may lead to dysregulations in obe-
sity, and further research must be developed. This approach 
will help researchers to clarify and understand the interac-
tions of the microbial metabolites with the host organism 
and to avoid misinterpretations when reporting allegedly 
dysregulated compounds that might be related to the micro-
biome or to the diet. For instance, metabolites such as hippu-
rate, isobutyryl glycine, and isovaleryl glycine, and TMAO 
were reported as biomarkers of obesity and might originate 
from microbial activity (Zheng et al. 2016a, b; Almanza-
Aguilera et al. 2018).
The field still faces many challenges. During the elabo-
ration of this review, we encountered many problems with 
the interpretation of the results due to the lack of a unified 
reporting scheme. Based on the metabolomics standards 
initiative (MSI) and core information for metabolomics 
reporting (CIMR) (Creek et al. 2014; Salek et al. 2015; 
Sumner et  al. 2007, 2014), these deficiencies must be 
improved, and this topic has been reviewed elsewhere 
(Considine et al. 2018). Furthermore, although a consen-
sus regarding the metabolites that comprise the metabolic 
signature of obesity has been achieved, further studies 
are needed to ensure the homologation, proper identifi-
cation and validation of these features to guarantee their 
reliability.
In the present study, we have used the quality assessment 
tool QUADOMICS and, although it has been adapted for 
omics studies, we found some deficiencies in metabolomics 
reporting. Our major concern is related to the evaluation of 
the reporting of identification. This topic should be covered 
in-depth to provide the reader with a concise view of the 
level of identification of the features reported and thus, inte-
grating these criteria might strengthen the reliability of the 
findings. For instance, a correct identification will provide 
tools to discriminate between endogenous and exogenous 
metabolites and reduce misinterpretations correctly. There-
fore, researchers should develop a specific tool for assessing 
the quality of metabolomics studies. As a final reflection, 
the combined use of untargeted and targeted approaches 
should be acknowledged as complementary. Untargeted 
metabolomics is the best approach to generate a hypothesis 
or to detect compounds that were not initially contemplated 
or were utterly unknown, thus generating new knowledge. 
Nevertheless, several drawbacks must be considered when 
using untargeted approaches to advance the field, namely, 
the validation of protocols, workflows and standards, the 
consolidation of the features reported with a rational soft-
ware (including the correct grouping of adducts) and the 
correct use of databases. In addition, targeted studies are 
necessary to validate and quantify the changes in metabo-
lism in a more precise manner.
5  Conclusions
Metabolomics provides a better understanding of disease 
progression and metabolic pathways in obese subjects. 
The present SR provides valuable information on specific 
metabolite patterns as characteristics of obesity, such as the 
metabolically healthy and unhealthy phenotypes, and even 
possible metabolomic profiles associated with their compli-
cations. These metabolites can be considered as biomarkers 
of obesity and improve our understanding of disease pro-
gression and metabolic pathways. Nevertheless, significant 
progress is needed, and further studies are required to test 
whether the proposed metabolites are considered an estab-
lished and specific metabolic signature. If this goal is accom-
plished, the signature might be useful as a clinical tool and 
for the development of more accurate clinical treatments 
focused on the pathogenesis of obesity and its potential 
comorbidities.
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